Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International Raises $1.4M

NEW YORK (GenomeWeb) – Proteomics International Laboratories said today it has raised $1.4 million through the placement of 6 million shares of stock at $.24 per share.

The company also announced a share purchase plan for an additional 2 million shares, intending to raise an additional $480,000 at $.24 per share from existing shareholders.

Proteomic International said it will use $500,000 to commercialize its PromarkerD test, a proteomic test for diagnosing and predicting risk of diabetic kidney disease, and another $500,000 to launch an analytical testing services business aimed at the clinical trials market. Both actions will continue to push the company towards cash-flow positive operations, Proteomics International said in a statement.

The balance of the proceeds will be used to fund day-to-day operations.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.